EUVIMEDEUVIMED entdecken
Crossref

Trends In Authorized Generic Drug Launches And Their Effects On Competition In Oral-Solid Drug Markets In The US, 2016–23

Keith M Drake, Gered Dunne, Aime Mason, Thomas G McGuire, Amie Price

Health Affairs · 2025

DOI: 10.1377/hlthaff.2024.01058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs, 2025. Verfasst von Keith M Drake und 4 weiteren Autor:innen. Beteiligte Einrichtung: Keith M. Drake (kdrake@gma-us.com), Greylock McKinnon Associates, Hanover, New Hampshire. Hauptthemen laut MEDLINE: Drugs, Generic, Economic Competition, Drug Industry, Drug Approval. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An authorized generic is a brand manufacturer's drug marketed as a generic product. It is the first traditional generic entrant's only potential competition during the 180-day generic exclusivity period. However, the brand manufacturer's ability to withhold its authorized generic represents a valuable bargaining chip that the manufacturer can offer the first traditional generic entrant in exchange for a later start date for generic competition. With data on 146 oral-solid drugs experiencing first generic entry during the period 2016-23, we found evidence for both positive and negative effects of authorized generics on competition. On-invoice prices that pharmacies paid for new generics were 13-18 percent lower when an authorized generic was available. However, authorized generic launches, which were once common, declined markedly in more recent years, which may be partly explained by no-authorized-generic agreements in brand-generic patent litigation settlements. Curtailing these agreements could greatly benefit drug purchasers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, GenericEconomic CompetitionDrug IndustryDrug ApprovalUnited StatesHumansAdministration, OralDrug CostsPatents as Topic

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • Keith M. Drake (kdrake@gma-us.com), Greylock McKinnon Associates, Hanover, New Hampshire.
  • Gered Dunne, Greylock McKinnon Associates, Hanover, New Hampshire.
  • Aime Mason, Greylock McKinnon Associates, Hanover, New Hampshire.
  • Thomas G. McGuire, Harvard University, National Bureau of Economic Research, and Greylock McKinnon Associates, Boston and Cambridge, Massachusetts.
  • Amie Price, Greylock McKinnon Associates, Hanover, New Hampshire.

Zitieren

APA

Drake, K. M., Dunne, G., Mason, A., McGuire, T. G., & Price, A. (2025). Trends In Authorized Generic Drug Launches And Their Effects On Competition In Oral-Solid Drug Markets In The US, 2016–23. Health Affairs. https://doi.org/10.1377/hlthaff.2024.01058

Vancouver

Drake KM, Dunne G, Mason A, McGuire TG, Price A. Trends In Authorized Generic Drug Launches And Their Effects On Competition In Oral-Solid Drug Markets In The US, 2016–23. Health Affairs. 2025. doi:10.1377/hlthaff.2024.01058

BibTeX
@article{Drake2025,
  author = {Drake, Keith M and Dunne, Gered and Mason, Aime and McGuire, Thomas G and Price, Amie},
  title = {Trends In Authorized Generic Drug Launches And Their Effects On Competition In Oral-Solid Drug Markets In The US, 2016–23},
  journal = {Health Affairs},
  year = {2025},
  doi = {10.1377/hlthaff.2024.01058}
}
Kostenlos starten →